IDH2 and central nervous system cancer: To this end, and IDH‐mutant low‐grade glioma model was established using Idh1 Lox‐Stop‐Lox (LSL)‐R132H/+ knock‐in mice [115, 197], and was crossed with a conditional Trp53 LSL‐R270H/+ (p53 gain of function) mice.